<DOC>
	<DOCNO>NCT01956253</DOCNO>
	<brief_summary>This study single subject study evaluate efficacy HER2 kinase inhibitor , neratinib , patient metastatic bladder cancer harbor HER2-GRB7 gene fusion .</brief_summary>
	<brief_title>Single Subject Neratinib Bladder Cancer ( NRR )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>* none * none We receive FDA approval single subject Investigational New Drug ( IND ) Application treat specific patient HER2 kinase inhibitor neratinib . Therefore inclusion / exclusion criterion .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Neratinib</keyword>
	<keyword>13-2526</keyword>
</DOC>